Verseon (LSE:VERS) Dividend Payout Ratio : 0.00 (As of Jun. 2019)

View and export this data going back to 2015. Start your Free Trial

What is Verseon Dividend Payout Ratio?

Verseon's dividend payout ratio for the months ended in Jun. 2019 was 0.00.

The historical rank and industry rank for Verseon's Dividend Payout Ratio or its related term are showing as below:

LSE:VERS's Dividend Payout Ratio is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.435
* Ranked among companies with meaningful Dividend Payout Ratio only.

As of today (2024-05-25), the Dividend Yield % of Verseon is 0.00%.

Verseon's Dividends per Share for the months ended in Jun. 2019 was £0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Verseon Dividend Payout Ratio Historical Data

The historical data trend for Verseon's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verseon Dividend Payout Ratio Chart

Verseon Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dividend Payout Ratio

Get a 7-Day Free Trial

Verseon Semi-Annual Data
	Dec11	Dec12	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19
Dividend Payout Ratio	Get a 7-Day Free Trial									-	-	-	-	-

Competitive Comparison of Verseon's Dividend Payout Ratio

For the Biotechnology subindustry, Verseon's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Verseon's Dividend Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Verseon's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where Verseon's Dividend Payout Ratio falls into.

Verseon Dividend Payout Ratio Calculation

Dividend payout ratio measures the percentage of the company's earnings paid out as dividends.

Verseon's Dividend Payout Ratio for the fiscal year that ended in Dec. 2018 is calculated as

Dividend Payout Ratio	=	Dividends per Share (A: Dec. 2018 )	/	EPS without NRI (A: Dec. 2018 )
	=	0	/	-0.111
	=	N/A

Verseon's Dividend Payout Ratio for the quarter that ended in Jun. 2019 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Jun. 2019 )	/	EPS without NRI (Q: Jun. 2019 )
	=	0	/	-0.063
	=	N/A

Verseon (LSE:VERS) Dividend Payout Ratio Explanation

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

Verseon Dividend Payout Ratio Related Terms

Thank you for viewing the detailed overview of Verseon's Dividend Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Verseon (LSE:VERS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Verseon Corp (LSE:VERS) » Definitions » Dividend Payout Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

47071 Bayside Parkway, Fremont, CA, USA, 94538

Website

http://www.verseon.com

Verseon Corp is a part of the healthcare sector in the United States. It is a technology-based pharmaceutical company with a computer-driven drug discovery platform. The company designs novel drug candidates that are unlikely to be found using conventional methods. It is also engaged in drug discovery programs such as the diabetic macular edema product candidates, which treat the diseases by controlled disruption of the kallikrein kinin cascade.